TELA Bio (NASDAQ:TELA) Given New $1.00 Price Target at Piper Sandler

TELA Bio (NASDAQ:TELA) had its target price cut by Piper Sandler from $1.25 to $1.00 in a research note released on Wednesday,Benzinga reports. They currently have a neutral rating on the stock.

Several other equities research analysts have also recently weighed in on TELA. Lake Street Capital lowered their price target on shares of TELA Bio from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Wednesday. Canaccord Genuity Group reduced their price objective on shares of TELA Bio from $4.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday. Loop Capital set a $3.00 target price on TELA Bio in a report on Monday, December 1st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TELA Bio in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, TELA Bio presently has an average rating of “Hold” and an average price target of $2.60.

TELA Bio Trading Down 9.4%

Shares of NASDAQ TELA opened at $0.69 on Wednesday. The company has a quick ratio of 2.62, a current ratio of 3.30 and a debt-to-equity ratio of 26.65. The business has a fifty day simple moving average of $0.85 and a two-hundred day simple moving average of $1.14. The firm has a market cap of $27.84 million, a PE ratio of -0.83 and a beta of 0.88. TELA Bio has a twelve month low of $0.62 and a twelve month high of $2.20.

TELA Bio (NASDAQ:TELA) last released its quarterly earnings data on Tuesday, March 24th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $20.87 million during the quarter, compared to analyst estimates of $21.04 million. TELA Bio had a negative net margin of 48.37% and a negative return on equity of 396.31%. Analysts expect that TELA Bio will post -1.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd bought a new position in shares of TELA Bio during the 4th quarter worth approximately $48,000. WealthTrust Axiom LLC boosted its stake in TELA Bio by 39.1% in the fourth quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company’s stock valued at $381,000 after acquiring an additional 90,650 shares in the last quarter. Renaissance Technologies LLC grew its holdings in TELA Bio by 101.4% in the fourth quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock worth $152,000 after purchasing an additional 64,800 shares during the last quarter. Essex Woodlands Management Inc. increased its position in shares of TELA Bio by 87.7% during the fourth quarter. Essex Woodlands Management Inc. now owns 7,714,709 shares of the company’s stock worth $9,103,000 after purchasing an additional 3,604,000 shares in the last quarter. Finally, Perkins Capital Management Inc. increased its position in shares of TELA Bio by 67.6% during the fourth quarter. Perkins Capital Management Inc. now owns 1,397,418 shares of the company’s stock worth $1,649,000 after purchasing an additional 563,490 shares in the last quarter. Hedge funds and other institutional investors own 94.35% of the company’s stock.

More TELA Bio News

Here are the key news stories impacting TELA Bio this week:

• Positive Sentiment: Q4 EPS slightly beat estimates: TELA reported GAAP EPS around ($0.16), modestly better than consensus (~$0.18) — a small beat that can be seen as stabilizing after prior losses. Earnings release & transcript
• Positive Sentiment: Management targets growth in 2026: the company is guiding to at least ~8% revenue growth for 2026 while pursuing a commercial transformation — a constructive forward signal if execution holds. Guidance article
• Positive Sentiment: Some analysts remain bullish: Lake Street and Canaccord kept buy ratings (while lowering price targets to $2.00), signaling continued upside expectations from certain brokerages. Canaccord/Lake Street note
• Neutral Sentiment: Revenue roughly in line / mixed read: Q4 revenue was $20.87M vs. consensus ~$21.04M — effectively flat to a slight miss, leaving mixed interpretation depending on margin trends and execution. Press release
• Neutral Sentiment: Readouts and call transcripts available: investors can review the full earnings release and multiple call transcripts for details on commercial initiatives and margin outlook. Earnings call transcript
• Neutral Sentiment: Trading activity is elevated: intraday volume is well above recent average — higher volume often amplifies price moves and reflects stronger investor attention (could be either direction).
• Negative Sentiment: Analysts cut forecasts / price-target trims: multiple firms adjusted models after the quarter — Piper Sandler cut its target to $1.00 and moved to Neutral; Benzinga and other coverage describe broader analyst downward revisions. This reduces near-term upside consensus. Analyst cuts article
• Negative Sentiment: Profitability & balance-sheet metrics remain challenging: the company still posts negative net margins and very high negative ROE; debt-to-equity and small market cap increase execution and volatility risk for investors. Zacks coverage
• Negative Sentiment: Short-interest reports show anomalous data: multiple notices flagged a “large increase” but reported zero/NaN figures — treat these data as unreliable until clarified; a true rise in short interest would be bearish.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.